CervoMed to present nfvPPA biomarker data in late-breaking session at ISFTD 2026Sep 10Clinical readoutCervoMed Inc.
CervoMed/EIP Pharma trial posts results for neflamapimod in Lewy body dementiaSep 3Trial updateCervoMed Inc.
CervoMed reports Q2 2026 results, seeks partner for neflamapimod Phase 3 in DLBAug 10Quarterly updateCervoMed Inc.
CervoMed's neflamapimod gets UK Innovation Passport for Lewy body dementiaAug 4PartnershipCervoMed Inc.
CervoMed presents new neflamapimod data at AAIC, backs 50 mg dose for DLB Phase 3Jul 14Clinical readoutCervoMed Inc.
Sign in